Mylan to Buy Abbott's Non-US Specialty, Branded Generics Assets

Generic drugmaker Mylan Inc. said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

Abbott will receive 105 million shares of the combined company.